Study of safety and immunogenicity of animal pasteurellosis vaccine

The article presents the results of a study on the safety and immunogenicity of monoand polyvalent vaccines designed for the specific prevention of pasteurellosis in animals, based on the genetically attenuated strain of P. multocida Aro/A serotype B.The monovalent vaccine, made from P. multocida serotype B, was administered to calves in a dose of 2.5x108 CFU (colony-forming units), and to sheep and goats in a dose of 2.5x109 CFU. The polyvalent vaccine, containing a genetically attenuated strain of P. multocida Aro/A and microbial cells of P. multocida serotype D in equal proportions (1:1), was administered to calves and piglets in a dose of 2.5x108 CFU, and to sheep and goats in a dose of 2.5x109 CFU.To evaluate the immunogenicity of the vaccines, animals were infected with the epizootic strain of P. multocida T88 on the 28th day after vaccination. Following infection, no signs of pasteurellosis were observed in any of the experimental animals: there were no indications of pain, redness or rashes at the body and injection sites, weakness, coughing, or elevated body temperature.The results of the conducted studies confirm the safety and immunogenicity of the mono- and polyvalent vaccines prepared from the attenuated strain of P. multocida Aro/A for animals.